Early treatment of CMT disease
The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.
1. A method of treating Charcot Marie Tooth type 1A disease (CMT1A) in a subject bearing a duplication or mutation of a PMP22 gene, comprising the step of administering to the subject a combination of baclofen, sorbitol, and naltrexone, or a pharmaceutically acceptable salt thereof, effective to treat CMT1A; wherein the subject is a human of 2 years of age or less and is at an early stage of the disease.
2. The method according to claim 1 , wherein the duplication or mutation of the PMP22 gene in the subject is identified by a genetic test.
3. The method according to claim 1 , wherein the subject is about 1 year of age or less.
4. The method according to claim 1 , wherein the subject is about 6 months of age or less.
5. The method according to claim 1 , wherein the subject is showing no or few physiological or morphological signs of CMT1A.
6. The method according to claim 5 , wherein the subject has a Charcot-Marie-Tooth Neuropathy Score (CMTNS) below 8.
7. The method according to claim 5 , wherein the subject has a Charcot Marie Tooth Disease Pediatric Scale score (CMTPedS) below 30.
8. The method according to claim 5 , wherein the subject has an Overall Neuropathy Limitations Scale score (ONLS) of 0.
9. The method according to claim 5 , wherein the subject is asymptomatic.
10. The method according to claim 1 , comprising administering to the subject simultaneously or sequentially a combination of baclofen, naltrexone, and sorbitol, wherein the baclofen is administered at a dose of between about 0.3 mg and about 12 mg, sorbitol at a dose of between about 10.5 mg and about 420 mg, and naltrexone at a dose between about 0.035 mg and about 1.4 mg.
11. The method according to claim 1 , wherein the baclofen, sorbitol, and naltrexone are administered sequentially or simultaneously at a relative weight ratio of baclofen/sorbitol/naltrexone of x/y/1, wherein: x is between about 2 and about 20; and y is between about 100 and about 500.
12. The method according to claim 10 , wherein the baclofen, sorbitol, and naltrexone are administered sequentially or simultaneously at a relative weight ratio of baclofen/sorbitol/naltrexone of about 8.6/300/1.
13. The method according to claim 12 , wherein the baclofen is administered at a dose of between about 0.3 mg and about 12 mg, sorbitol at a dose of between about 10.5 mg and about 420 mg, and naltrexone at a dose between about 0.035 mg and about 1.4 mg.
14. The method according to claim 1 , wherein the subject is administered a combination of (R/S) baclofen, sorbitol, and naltrexone.
15. The method according to claim 12 , wherein the subject is administered a combination of (R/S) baclofen, sorbitol, and naltrexone.
16. The method according to claim 1 , wherein the combination is administered chronically to the subject.
17. The method according to claim 13 , wherein the combination is administered chronically to the subject.
18. The method according to claim 15 , wherein the combination is administered chronically to the subject.